Latest filings (excl ownership)
8-K
Haemonetics Corporation Completes Acquisition of Attune Medical
1 Apr 24
8-K
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
5 Mar 24
10-Q
2024 Q3
Quarterly report
8 Feb 24
8-K
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal 2024 Guidance
8 Feb 24
8-K
Other Events
12 Dec 23
10-Q
2024 Q2
Quarterly report
2 Nov 23
8-K
Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2024 Guidance
2 Nov 23
8-K/A
Financial Statements and Exhibits
12 Oct 23
8-K
Entry into a Material Definitive Agreement
10 Oct 23
S-8
Registration of securities for employees
11 Aug 23
10-Q
2024 Q1
Quarterly report
8 Aug 23
8-K
Haemonetics Reports First Quarter Fiscal 2024 Results; Updates Fiscal 2024 Guidance
8 Aug 23
8-K
Departure of Directors or Certain Officers
7 Aug 23
ARS
2023 FY
Annual report to shareholders
16 Jun 23
DEFA14A
Additional proxy soliciting materials
16 Jun 23
DEF 14A
Definitive proxy
16 Jun 23
SD
Conflict minerals disclosure
30 May 23
10-K
2023 FY
Annual report
22 May 23
8-K
Results of Operations and Financial Condition
11 May 23
10-Q
2023 Q3
Quarterly report
7 Feb 23
8-K
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal 2023 Guidance
7 Feb 23
10-Q
2023 Q2
Quarterly report
8 Nov 22
8-K
Haemonetics Reports Second Quarter and First Half Fiscal 2023 Results; Updates Fiscal 2023 Guidance
7 Nov 22
8-K
Departure of Directors or Certain Officers
19 Oct 22
10-Q
2023 Q1
Quarterly report
10 Aug 22
8-K
Haemonetics Reports First Quarter Fiscal 2023 Results; Updates Fiscal 2023 Guidance; Announces New $300 Million Share Repurchase Authorization
10 Aug 22
8-K
Departure of Directors or Certain Officers
8 Aug 22
8-K
Entry into a Material Definitive Agreement
1 Aug 22
DEFA14A
Additional proxy soliciting materials
17 Jun 22
DEF 14A
Definitive proxy
17 Jun 22
8-K
Departure of Directors or Certain Officers
16 Jun 22
SD
Conflict minerals disclosure
26 May 22
8-K
Departure of Directors or Certain Officers
25 May 22
10-K
2022 FY
Annual report
25 May 22
8-K
Results of Operations and Financial Condition
10 May 22
8-K
Departure of Directors or Certain Officers
21 Mar 22
8-K
Regulation FD Disclosure
15 Feb 22
10-Q
2022 Q3
Quarterly report
8 Feb 22
8-K
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2022 Results; Updates Fiscal 2022 Guidance
8 Feb 22
10-Q
2022 Q2
Quarterly report
9 Nov 21
Latest ownership filings
4
Anila Lingamneni
17 Apr 24
4
Christopher Simon,
13 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Neuberger Berman Group LLC
13 Feb 24
SC 13G/A
Capital Research Global Investors
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Roy Galvin
3 Nov 23
4
Michelle L Basil
24 Oct 23
4
Stewart W Strong
24 Oct 23
4
Laurie A. Miller
18 Sep 23
4
Anila Lingamneni
13 Sep 23
4
Stewart W Strong
13 Sep 23
144
Notice of proposed sale of securities
12 Sep 23
144
Notice of proposed sale of securities
11 Sep 23
4
Charles J Dockendorff
7 Sep 23
144
Notice of proposed sale of securities
5 Sep 23
4
Diane M Bryant
8 Aug 23
4
Charles J Dockendorff
8 Aug 23
4
Ellen M Zane
8 Aug 23
4
Claire Pomeroy
8 Aug 23
4
MARK W KROLL
8 Aug 23
4
Lloyd Emerson Johnson
8 Aug 23
4
MICHAEL J COYLE
8 Aug 23
4
ROBERT E ABERNATHY
8 Aug 23
3
Diane M Bryant
8 Aug 23
4
Josep Llorens
20 Jul 23
144
Notice of proposed sale of securities
18 Jul 23
4
Christopher Simon,
30 Jun 23
4
Stewart W Strong
9 Jun 23
144
Notice of proposed sale of securities
7 Jun 23
4
Laurie A. Miller
5 Jun 23
4
Anila Lingamneni
1 Jun 23
144
Notice of proposed sale of securities
30 May 23
4
Michelle L Basil
19 May 23
4
Anila Lingamneni
19 May 23
4
Josep Llorens
19 May 23
4
Laurie A. Miller
19 May 23
4
Christopher Simon,
19 May 23
4
Stewart W Strong
19 May 23